explore -WSS

explore

author：focus 2025-09-28 23:48:08 - browse：5596

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： FDA's naming rule on biosimilars has undermined competition

knowledge

WSS

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Why the world’s most expensive drug might be worth the price

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Primary care physicians play key roles in Alzheimer's management

Hottest summer in 2,000 years puts focus on extreme heat, health

STAT series 'Denied by AI' wins major journalism prizes

knowledge

explore

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

The White House hikes tariffs on plastic syringes made in China

Supreme Court strikes down use of affirmative action

STAT reporters are Pulitzer Prize finalists for investigative reporting

Duchenne breakthrough therapy leaves behind pioneering families

Supreme Court mifepristone arguments center on docs' right to sue

23andMe had bad news about my health. I wish a person had delivered it

Steward Health Care has deal to sell doctor network to UnitedHealth

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

hotspot

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Donor acceptance rates hint at racial, gender bias in heart transplants: study

ALS treatment from Biogen, Ionis fails in study

Study says nonprofit hospitals fall short in charity care spending

Ripples from Flovent's discontinuation is killing children with asthma

explore

knowledge

Wikipedia

leisure time